Know which accounts are deciding next.

Sextant & Rule shows your sales team which clinical programs in your market are between studies, what changed this month, and who to call. Every claim links to the public record.

Name a sponsor. We'll show you where they stand.
Sextant

The reading

A sextant measures the angle between a known star and the horizon, and from that one reading a navigator knows where the ship is.

Here the known star is the public trial record, sampled month after month, so a program can be measured against its own history.

Rule

The chart

A parallel rule transfers the fix onto the chart, where it finally means something. A position with no chart is just a number.

Your business is the chart: what you sell, to whom, and what has to be true before a program is worth your time.

How it works

There is no shortage of trial data. What's missing is where a specific program sits in its own arc, measured against what matters to your business.

01

Define your market

The therapeutic areas, phases, services and sponsors that fit what you sell. You confirm it, and you own it.

02

We take the fix

Each month we compare registry snapshots and SEC filings to find what moved: new programs, phase changes, slipped dates, stalled studies.

03

You act first

A ranked chart, plus benchmarks against peer programs and alerts when an account starts deciding (both launching December).

What we tell you

Three readings, taken against your market every month.

Reading 01Programs between studies

A compound that finished a phase with no next study filed. The next protocol isn't written yet, so scope, vendors and budget are still open.

Reading 02What moved since last month

New programs entering your scope, phase changes, slipped completion dates and revised enrollment targets, filtered to the slice that is yours.

Reading 03Where each account stands

A sponsor-level picture: how many programs they run, at what phases, and whether activity is expanding or winding down. Readable before the call.

Why early matters

Most trials appear on the registry around the month they start, after vendors are chosen. We watch the gap between studies, when the next protocol is being written and nothing is decided yet.

What you get

The chart

One card per account, ranked, with the record behind every line.

Benchmarks, launching December

How each program's timing compares with its peers, with the sample size shown.

Alerts, launching December

A flag when an account passes the point where its peers made their next move.

Built from public sources, each doing a different job. The trial registry produces the position. Corporate structure establishes who the sponsor actually is, so one customer isn't split across six account names. SEC filings add cash, burn and runway where a company files. Every line names the record it was read from.

Who it's for

CROs, site networks, labs, imaging, logistics and eClinical teams selling into clinical development.

Service providersCROs, site networks, central and specialty labs, imaging core labs, logistics, biometrics, packaging
Technology vendorseClinical, EDC, eCOA and RTSM platforms selling into study teams
Sponsors and biotechCompetitive and landscape intelligence on programs adjacent to your own
Investors and advisorsAnyone whose thesis depends on how a development program is actually progressing

See it on a sponsor you know.

Pick a company you know well and we'll read its position back to you, so you can judge us against what you already know.

Start a conversation